Aspiro Therapeutics CEO James Lovgren to Speak at Global RESCON Summit 2026

Tucson, Arizona | September 3, 2026 – Aspiro Therapeutics will participate in the Global RESCON Summit 2026, where Chief Executive Officer and Co-Founder James Lovgren will serve as a featured speaker. Taking place November 10–11, 2026, in Porto, Portugal, the conference brings together leaders from industry, academia, regulatory agencies, and investment to discuss advances in inhaled therapeutics, respiratory drug delivery, and connected devices.

During the conference, James will present “From Concept to Inhalation: Early Development Lessons in Pulmonary Delivery of a Peptide,” highlighting Aspiro’s experience advancing ATX-1019 and sharing lessons learned from the company’s recent aerosol development program as it progresses toward clinical development.

In addition to his presentation, James will participate in the conference’s Investor Panel: “Building Investable Respiratory Platforms: What Drives Partnerships, Valuation & Scale,” joining leaders from Forge Life Science Partners, Vivo Capital, and AstraZeneca to discuss the milestones, partnerships, and strategic considerations shaping the future of respiratory innovation.

“We’re excited to contribute to the scientific and strategic discussions at this year’s RESCON Summit,” said James Lovgren, CEO and Co-Founder of Aspiro Therapeutics. “The meeting brings together a unique mix of scientists, industry leaders, and investors focused on advancing the next generation of inhaled therapeutics. I’m looking forward to sharing our experience and engaging with colleagues from across the respiratory community.”

Aspiro Therapeutics looks forward to connecting with researchers, industry partners, and investors during the meeting.

Learn more about the Global RESCON Summit